NASDAQ:ACHN

Achillion Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range N/A

50-Day Range

$6.76

▼

$6.76

52-Week Range N/A

VolumeN/A

Average Volume8.44 million shs

Market Capitalization$946.72 million

P/E RatioN/A

Dividend YieldN/A

Beta1.59

Receive ACHN News and Ratings via Email

Sign-up to receive the latest news and ratings for Achillion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Achillion Announces Pricing of Secondary Offering Of Common Stock
July 7, 2020 | www.bloomberg.com

Achillion Reports First Quarter 2018 Financial Results and Management Transition
June 7, 2020 | www.bloomberg.com

Lifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central European
June 2, 2020 | www.bloomberg.com

Achillion Appoints Nicholas Simon to Board of Directors
May 26, 2020 | www.bloomberg.com

Achillion Pharmaceuticals (ACHN) - Options Chain
March 22, 2020 | www.fool.com

Alexion Pharmaceuticals Is On Sale
February 3, 2020 | seekingalpha.com

14 Biotechnology Stocks Moving In Monday's Pre-Market Session
January 27, 2020 | www.benzinga.com

Achillion up 16% premarket on advancement of Alexion tie-up
January 27, 2020 | seekingalpha.com

Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study
January 8, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACHN
Previous Symbol
CUSIP00448Q20
CIK1070336
Webwww.achillion.com
Phone203-624-7000
Employees56
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.92 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)($0.51)
Net Income$-70,270,000.00
Net MarginsN/A
Return on Equity-30.95%
Return on Assets-29.09%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares140,047,000
Market Cap$946.72 million
Next Earnings DateN/A
OptionableOptionable

MarketRank^™

Overall MarketRank^™

0.85 out of 5 stars

Medical Sector

1208th out of 2,096 stocks

Pharmaceutical Preparations Industry

551st out of 830 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Achillion Pharmaceuticals.

2.6 Community Rank

Outperform Votes
Achillion Pharmaceuticals has received 492 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Achillion Pharmaceuticals has received 445 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Achillion Pharmaceuticals has received 52.51% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote “Outperform” if you believe ACHN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Achillion Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Achillion Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Achillion Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.58% of the stock of Achillion Pharmaceuticals is held by insiders.
Percentage Held by Institutions
79.42% of the stock of Achillion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Achillion Pharmaceuticals are expected to decrease in the coming year, from ($0.59) to ($0.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Achillion Pharmaceuticals is -12.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Achillion Pharmaceuticals is -12.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions

What stocks does MarketBeat like better than Achillion Pharmaceuticals?

Wall Street analysts have given Achillion Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Achillion Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.02.
View Achillion Pharmaceuticals' earnings history.

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the following people:

Mr. Joseph Truitt, Pres, CEO & Director (Age 54)
Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 64)
Mr. Brian R. Di Donato, CFO, SVP & Treasurer (Age 52)
Mr. Paul Firuta, Exec. VP & COO (Age 53)
Dr. Kevin P. Malobisky, Sr. VP of Regulatory Affairs, Quality & Compliance

Who are some of Achillion Pharmaceuticals' key competitors?

Some companies that are related to Achillion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of ACHN's competitors.

What other stocks do shareholders of Achillion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Iconix Brand Group (ICON), Celldex Therapeutics (CLDX) and Edap Tms (EDAP).

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How much money does Achillion Pharmaceuticals make?

Achillion Pharmaceuticals has a market capitalization of $0.00. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Achillion Pharmaceuticals have?

Achillion Pharmaceuticals employs 56 workers across the globe.

What is Achillion Pharmaceuticals' official website?

The official website for Achillion Pharmaceuticals is www.achillion.com.

Where are Achillion Pharmaceuticals' headquarters?

Achillion Pharmaceuticals is headquartered at 300 GEORGE STREET, NEW HAVEN CT, 06511.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.

This page was last updated on 6/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Achillion Pharmaceuticals Stock Forecast, Price & News

About Achillion Pharmaceuticals

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

2.6 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

1.7 Company Ownership

0.0 Earnings and Valuation

Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions

What stocks does MarketBeat like better than Achillion Pharmaceuticals?

How were Achillion Pharmaceuticals' earnings last quarter?

Who are Achillion Pharmaceuticals' key executives?

Who are some of Achillion Pharmaceuticals' key competitors?

What other stocks do shareholders of Achillion Pharmaceuticals own?

What is Achillion Pharmaceuticals' stock symbol?

How much money does Achillion Pharmaceuticals make?

How many employees does Achillion Pharmaceuticals have?

What is Achillion Pharmaceuticals' official website?

Where are Achillion Pharmaceuticals' headquarters?

How can I contact Achillion Pharmaceuticals?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™